LIST OF PEER REVIEW PUBLICATIONS (2016-2002)

Articles published in 2016

218. Renema N, Navet B, Heymann MF, Lezot F, Heymann D. RANK-RANKL signalling in cancer. Biosci Rep, in press.

217. BrulefertK, Cordova L, Brulin B, Faucon A, Hulin P, Nedellec S, Gouin F, Passuti N,Ishow E, Heymann D.  Polyethylene nanoparticles are internalizedby human macrophages and osteoclasts and promotes osteoclast differentiation. J Biomed Mat Res A, in press

216. Jacques C , Lamoureux F,Baud'huin M , Rodriguez Calleja L , Quillard T, Amiaud J, Perrot P, Tirode F,Redini F , Bradner J , Heymann D,Ory B. Selective inhibition of BET bromodomain epigenetic signaling interfereswith EWS-FLI1 expression in Ewing Sarcoma. Oncotarget,in press.

215. Ory B, Baud'huin M, Verrecchia F, Brounais-Le Royer B, Quillard T,Amiaud J, Battaglia S, Heymann D,Redini F, Lamoureux F. Blocking HSP90 addiction inhibits tumor cell proliferation,metastasis development and synergistically acts with zoledronic acid to delayosteosarcoma progression. Clin CancerRes, in press.

214. Tellez Gabriel M, Rodriguez Calleja L, Chalopin A, Ory B, Heymann D. Circulating tumor cells: areview of non EpCAM-based approaches for cell enrichment and isolation. Clin Chem2016;62(4):571-81.

213. Rodriguez Calleja L, Jacques, C, Lamoureux F, Baud'huin M, TellezGabriel M, Quillard T, Debashish S, Lecanda F, Verrecchia F, Heymann D, Ory B, Ellisen LW. DNp63a stimulates TGFb-induced metastasis through microRNA regulation. Cancer Res 2016; 76(11):3236-51

212. BiteauK, Guiho R, Chatelais M, Taurelle J, Chesneau J, Corradini N, Heymann D,Redini F. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.  Am J CancerRes 2016;6(3):677-89.

211. Bonissent A, Vabres B, Orignac I, Martin E,Libeau L, Heymann D, Ducourneau Y, Weber M. Excimer laser-assistedlamellar endothelial keratoplasty (ExALEK): Technique and results. J Fr Ophtalmol. 2016;39(2):178-86

210. Perrot P,Avril P, Ridel P, Heymann MF, De Pinieux G, Rédini F, Blanchard F, Heymann D,Trichet V, 215. Heymann D,Ruiz-Velasco C, Chesneau J, Ratiskol, Sinquin C, Colliec-Joault.Anti-metastatic properties of a marine bacterial exopolysaccharide-basedderivative designed to mimic glycosaminoglycans. Molecule 2016, 21(3) pii:309.

209. Perrot P. Opposite effects of soluble factorssecreted by adipose tissue on proliferating and quiescent osteosarcoma cells. Plasticand reconstructive Surgery, 2016, 137(3) :865-875.

208. Davaine JM, Quillard T, Chatelais M, Guilbaud F,Brion R, Guymorach B, Brennan MA, Heymann D, Heymann MF, Goueffic Y.Bone-like tissue artificial calcification in femoral atheroscleroticlesions: prevlence and role of osteoprotegeinr and pricytes. Eur J VascSurg, 2016, 51 : 259-267.

207. Avril P, Le Nail LR,Brennan M, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P, TrichetV. Interactions of adipose tissue- and bone marrow-derived stem cells withproliferating and quiescent osteosarcoma cells. J Bone Oncol, 2016, 5:5-14.

Articles published in 2015

206. SégalinyA, Brion R, Brulin B, Maillasson M, Charrier C, Teletchea S, Heymann D. Interleukin-34 andMacrophage Colony-Stimulating Factor form a novel heteromeric cytokine andregulate the M-CSF receptor activation and localization. Cytokine, 2015, 76(2):170-181.

205. Faucon A, Lenk R, Cordova LA, Brulin B,Heymann D, Hulin P, Nedelled S, Isho E. Fluorescent organic nanoparticlesas solvatochromic probes of cancer cell and monocyte/macrophage activity.Advanced Health Care Materials, 2015, 4(17):2727-34.

204. Redini F, Heymann D. Bone tumor environment aspotential therapeutic target in Ewing sarcoma. Frontier Oncol Section Pediatric Oncol, 2015, 5: 279.

203. Crémet L,Broquet A, Brulin B, Jacqueline C, Dauvergne S, Brion R,Asehnoune K, Corvec S, Heymann D,Caroff N. Interaction of Escherichia coliclinical strains with human osteoblastic cells: low invasion but high cytolyticpotential of some Hly-producing strains.Pathogens & Disease, 2015, 73:ftv065.

202. Sousa S, Brion R,Lintunens M, Kronqvist P, Sandholm J, Mökkönen J, Kellokupu-Lehtinen PL,Tynninen O, Joensuu H, Heymann D,Määttä J. Human breastcancer cells educate macrophages toward the M2 activation status. BreastCancer Research, 2015, 17 :101.

201. Lamora A, Mullard M,Amiaud J, Brion R, Heymann D, Redini F, Verrecchia F. Halofuginone inhibitsprimary tumor growth and lung metastasis development in osteosarcoma. Oncotargets, 2015, 6: 14413-14427.

200. Beranger GE, Djedaini M,Battaglia S, Roux CH, Heymann D,Amri EZ, Pisani DF. Oxytocin reversed osteoporosis in sex dependent manner. Frontiers In Endocrine Research Topics, 2015; 6:181.

199. Heymann MF, Renema N, Heymann D. Alpesilib:Phosphatidulinositol 3-kinase alpha (PI3Ka) inhibitor. Monograph. Drugs of the Future. 2015, 40: 213-223.

198. Ségaliny AI, Mohamadi A,Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C,Heymann D.  Interleukin-34 promotes the tumour progression and metastatic process inosteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer, 2015, 137:73-85.

197. Guihard P, Boutet MA, Brounais B, Gamblin AL, Renaud A, Berreur M,Redini F, Heymann D, Layrolle P,Blanchard F. Oncostatin M, an inflammatory cytokine produced by macrophages,supports intramembranous bone healing in a mouse model of tibia injury. Am J Pathol, 2015,  185(3): 765-775.

196. Ségaliny AI, Brion R,Mortier E, Maillasson M, Cherel M, Jacques Y, Le Goff B, Heymann D. Syndecan-1 regulates the biological activitiesof interleukin-34. BiochimBiophys Acta Mol Cell Res, 2015 1853(5):1010-1021

195. Segaliny AI, Tellez-Gabriel M, Heymann MF,Heymann D. Receptor tyrosine kinases: characterisation, mechanismof action and therapeutic interests for bone cancers. J Bone Oncol, 2015, 4:1-12.

194. Guiho R, Biteau K, Heymann D, Redini F. TRAIL-based therapy in pediatricbone tumors: how to overcome resistance. Future Oncol, 2015,11(3):535-542.

193.  Cordova LA,Trichet V, Escriou V,, Rosset P, Amiaud J, Battaglia S, Charrier C, Berreur M, Brion R, Gouin F, Passuti N, Heymann D. Inhibition of osteolysis and increase of bone formation after localadministration of siRNA-targeting RANKin a polyethylene-particle-induced osteolysis model. Acta Biomaterialia, 2015, 13:150-158.

192. Gobin B, Baud'huin M, Lamoureux F, Charrier C,Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D. BYL719,a new a-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer, 2015.136:784-96

191. Lezot F, Chesneau J, Navet B, Gobin B, Choi YW, Yagita H, MuellerC, Redini F, Heymann D. Skeletal consequences of RANKL blocking antibody (IK22-5) injections during growth:mouse strains disparities and synergic effect with Zoledronic acid. Bone, 2015, 73:51-59.

Articles published in 2014
190. Brennan MA, Renaud A, Amiaud J, Rojewski MT, Schrezenmeier H, Heymann D, Trichet V, Layrolle P. Preclinical studies of bone regeneration using GMP produced human mesenchymal stem cells associated with basic calcium phosphate. Stem Cell Research & Therapy 2014, 5:114.

189. Gamblin AL, Brennan MA, Renaud A, Yagita H, Lézot F, Heymann D, Trichet V, Layrolle P. Bone tissue formation with human mesenchymal stem cells and biphasic calcium phosphate ceramics: the local implication of osteoclasts and macrophages. Biomaterials, 2014, 35:9660-9667.

188. Darrieutort-Laffite C, Boutet MA, Chatelais M, Brion R, Blanchard F, Heymann D, Le Goff B, IL-1b and TNFa promote monocyte survival and proliferation through the induction of GM-CSF expression by synovial fibroblasts. Mediators of Inflammation, 2014, ID241840.

187. Lezot F, Chesneau J, Battaglia S, Brion R, Farges JC, Heymann D, Rédini F. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric population with bone malignancies. Bone, 2014, 68: 716-722.

186. Gamblin AL, Renaud A, Charrier C, Hulin P, Louarn G, Heymann D, Trichet V, layrolle P. Osteoblastic and osteoclastic differentiation of human mesenchymal stem cells and monocytes in a miniaturized three-dimensional culture with mineral granules. Acta Biomaterialia, 2014, 5:114.

185. Davaine JM, Quillard T, Brion R, Lapérine O, Merlini T, Gyyomarch B, Chatelais M, Guilbaud F, Brennan MA, Charrier C, Heymann D, Goueffic Y, Heymann MF. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS One, 2014,9:e107642.

184. Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Redini F. Clusterin inhibition using OGX-011 synergistically enhances zoledrconic acid activity in osteosarcoma. Oncotarget, 2014, 5:7805-7819.

183. Lamora A, Talbot J, Bougras G, Leduc M, Cheneau J, Taurelle J, Stresing V, Le Deley MC, Heymann D, Redini F, Verrecchia F. Overexpression of Smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. Clin Cancer Res, 2014, 20:5097-5112.

182. Nollet M, Santucci-Darmanin S, Breuil V, Al-Sahlanee R, Cros C, Topi M, Momier D, Samson M, Pagnotta S, Cailleteau L, Battaglia S, Farlay D, Dacquin R, Barois N, Jurdic P, Boivin G, Heymann D, Lafont F, Lu SS Dempster D, Carle GF, Pierrefite-Carle V. Autophagy in Osteoblasts is involved in Mineralization and Bone Homeostasis. Autophagy, 2014, 10:1965-1977.

181. Lau, AG, Sun J, Hanna WB, Livingston E, Heymann D, Bateman TA, Monahan P. Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone which is prevented with prophylactic factor replacement. Haemophilia, 2014, 20:716-722.

180. Télétchéa S, Stresing V, Hervouet S, Baud'huin M, Heymann MF, Bertho G, Charrier C, Ando K, Heymann D. Novel RANK antagonists for the treatment of bone resorptive disease: Theoretical predictions and experimental validation. J Bone Miner Res, 2014, 29:1466-1477.

179. Cordova Jara L, Stresing V, Gobin B, Rosset P, Passuti N, Gouin F, Layrolle P, Trichet V, Heymann D. Mouse models for the study of periprosthetic UHMWPE particles-induced osteolysis. Clinical Sciences, 2014, 127(5):277-293.

178. Rousseau J, Gioia R, Layrolle P, Lieubeau B, Heymann D, Rossi A, Marini JC, Trichet V, Forlino A. Allele specific silencing reduces mutant collagen in Brtl fibroblasts, a murine model for osteogenesis imperfecta. Eur J Human Genet, 2014, 22(5):667-674.

177. Lamoureux F, Baud'huin M, Rodriguez L, Jacques C, Lecanda F, Berreur M, Rédini F, Bradner JE, Heymann D, Ory B. Specific inhibition of BET bromodomains interferes with the vicious cycle of bone tumor development. Nature Commun, 2014, 19;5:3511.

176. Beranger GE, Pisani DF, Castel J, Djedaini M, Battaglia S, Amiaud J, Boukhechba F, Ailhaud G, Michiels JF, Heymann D, Luquet S, Ez-Zoubir A. Oxytocin reverses ovariectomy-induced osteoporosis and intra-abdominal adiposity. Endocrinology, 2014, 155:1340-52.

175. Odri G, Kim P, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Rédini F. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. BMC Cancer, 2014, 14:169.

174. Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Redini F, Ory B, Heymann D. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Letters, 2014, 344:291-298.

173.  Gobin B, Moriceau G, Ory B, Charrier C, Brion R, Blanchard F, Rédini F, Heymann D. Therapeutic interest of imatinib mesylate in osteosarcoma: an open debate. PloS One, 2014;9(3):e90795.

Articles published in 2013
172. Le Goff B, Berthelot JM, Maugars Y, Heymann D. Osteoclasts in RA: Diverse origins and functions. Joint Bone Spine, 2013, 80:586-591.

171. Monderer D, Luseau A, Bellec A, David E, Ponsolle S, Saiagh S, Bercegeay S, Piloquet P, Denis M, Lobé L, Rédini F, Biger  M, Heymann D, Heymann MF, Le Bot R, Gouin F, Blanchard F. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Lab Invest, 2013, 93: 100-1114.

170.  Baud'huin M, Duplomb L, Télétchéa S, Ruiz-Velasco C, Maillasson M, Rédini F, Heymann MF, Heymann D.  Osteoprotegerin : multiple partners for multiple functions. Cytokine Growth Factors Rev, 2013, 14:401-409.

1
69. Heymann D, Rédini F. Targeted therapies for bone sarcomas. BoneKey Reports, 2013, 2:378.

168.  Redini F, Odri G, Picarda G, Gaspar N, Heymann MF, Corradini N, Heymann D. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? Expert Opinion on Emerging Drug, 2013 18(3):339-352.

167. Deschaseaux F, Gaillard J, Langonné A, Chauveua C, Naji A, Bouacida A, Rosset P, Heymann D, De Pinieux G, Rouas-Freiss, Sensebé, L. Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J, 2013, 27:2977-2987.

166. Picarda G, Matous E, Amiaud J, Charrier C, Lamoureux F, Heymann MF, Tirode F, Pitard B, Trichet V, Heymann D, Rédini F. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL. J Bone Oncol, 2013, 2: 95-104.

165. Miot-Noirault E,  David E, Vidal A, Besse S, Dauplat MM, Gouin F, Heymann D, Rédini F. Therapeutic efficacy of zoledronic acid in the swarm rat chondrosarcoma model assessed by 99mTc-NTP 15-5 scintigraphic imaging. European Journal of Nuclear Medicine and Molecular Imaging Research, 2013, 3(1):40.

164. Georges S, Chesneau J, Hervouet S, Taurelle J, Rédini F, Padrines M, Heymann D, Fortun Y, Verrecchia F. ADAM12 produced by tumor cells accelerates osteosarcoma tumor progression and associated osteolysis.  Eur J Cancer, 2013, 49:2253-2263.

163. Ando K, Heymann MF, Stresing V, Kanji M, Redini F, Heymann D. Current therapeutic strategy and novel approaches in osteosarcoma. Cancers, special issue: Soft Tissue and Bone Sarcoma, 2013, 5 : 591-616.

162. Benslimane-Ahmin Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-Fauroux I, Mouhamedi A, Fischer AM, Heymann D, Lutomski D, Boisson-Vidal C. Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis, 2013, 16:575-593.

161.
Lionetto S, Little A, Moriceau G, Heymann D, Decurtins M, Plecko M, Filgueria L, Cadosh D. Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro. J Biomed Mat Res A, 2013, 101:991-997.

160. Odri GA, Revert R, Deschamps C, Romih M, Maugars Y, Heymann D, Delecrin J. Effect of adding bone marrow to ceramic graft materials with different interconnectivities in lumbar arthrodesis : Quantification of bone formation. J Orthop Sci. 2013, 18:321-330.

159. Milan JL, Lavenus S, Pilet P, Louarn G, Wending S, Heymann D, Layrolle P, Chabrand P. Computational model combined with in vitro experiments to analyze mechanotransduction during mesenchymal stemm cell adhesion. Eur Cell Materials, 2013, 25: 97-113.

158. Talbot J, Brion R, Picarda G, Amiaud J, Chesneau J, Stresing V, Tirode F, Heymann D, Rédini F, Verrecchia F. Loss of connexin-43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated osteolysis. Biochim Biophys Acta-Molecular Basis of Disease, 2013, 1832:553-564.

157.
Arterial heterogeneity. Gouëffic Y, Davaine JM, Merlini T, Rimbert A, Hérisson F, Heymann MF, Heymann D, Steenman M, Lambert G. Rev Med Interne 2013, 34(1):61-5.

Articles published in 2012
156. Odri GA, Hami A, Pomero V, Seite M, Heymann D, Bertrand-Vasseur A, Skalli W, Delecrin J. Development of a per-operative procedure for concentrated bone marrow adjunction in postero-lateral lumbar fusion: Radiological, biological and clinical assessment. Eur Spine J. 2012, 21:2665-2672.
155. Bouacida A, Rosset P, Trichet V, Cordonier T, Heymann D, Layrolle P, Sensebé L, Deschaseaux F. Bone marrow mesenchymal stem cells cultured in pericytic conditions exhibit a highly immature state. PLoS ONE, 2012, 7(11):e48648.

154. David E, Tirode F, Baud'huin M, Guihard P, Laud K, Delattre O, Heymann MF, Heymann D, Rédini F, Blanchard F. Oncostatin M is a growth factor for Ewing sarcoma. Am J Pathol., 2012, 181: 1782-1795.

153.  Heymann D. Anti-RANKL therapy for bone tumours: basic, pre-clinical and clinical evidences. J Bone Oncol, 2012, 1:2-11.

152.
Peyrode C, Weber V, David E, Vidal A, Auzuloux, Communal Y, Dauplat MM, Besse S, Gouin F, Heymann D, Chezal JM, Redini F, Miot-Noirault E. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies. Invest New Drugs, 2012, 30:1782-90.

151.
Heymann MF, Herisson, Davaine JM, Charrier C, Battaglia S, Passuti N, Lambert G, Goueffic Y, Heymann D. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine, 2012, 58:300-306.

150. Guihard P, Danger Y, Brounais B, David E, Brion R, Delécrin J, Richards CD, Chevalier S, Rédini F, Heymann D, Gascan H, Blanchard F. Induction of bone formation by activated monocytes/macrophages depends on Oncostatin M signaling. Stem Cells, 2012, 30:762-772.

149. Picarda G, Surget S, Guiho R, Téletchéa S, Berreur M, Tirode F, Pellat-Deceunynck C, Heymann D, Trichet V, Rédini F. A functional, new short isoform of detah receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms. Mol Cancer Res, 2012,10:336-346.

148. Ando K, Mori K, Verrecchia F, Baud'huin M, Rédini F, Heymann D. Molecular alterations associated with osteosarcoma development. Sarcoma, 2012:523432.

147.
Anjubault T, Martin J, Hubert FX, Chauvin C, Heymann D, Josien R. Constitutive expression of TNF-related activation - induced cytokine (TRANCE)/Receptor Activator of NFkB (RANK)-L by rat plasmacytoid dendritic cells. PLoS ONE 2012;7(3):e33713.

146.
Miot-Noirault E, Gouin F, Dauplat MM, Heymann D, Chezal JM, Redini F. Relevance of the Pos-1 orthotopic model as an imaging model for in vivo and simultaneous monitoring of tumor proliferation and bone remodelling in osteosarcoma. Cancer Biother Radiopharm 2012, 27:96-103.

145. Moriceau G, Roelofs A, Brion R, Redini F, Ebetino FH, Rogers MJ, Heymann D. Synergistic effect of apomine and lovastatin on osteosarcoma cell growth. Cancer 2012,118:750-60. Selected by the Faculty of 1000.

144. Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, Bougras G, Touchais S, Blanchard F, Heymann MF, Berthelot JM, Verrecchia F, Heymann D. Interleukin-34 expression is associated with synovitis severity in rheumatoid arthritis. Ann Rheum Dis, 2012, 71:150-154.

Articles published in 2011
143. Le Goff B, Heymann D. Pharmacodynamics of bisphosphonates in arthritis. Expert rev Clin Pharmacol 2011, 4: 633-641.

142. Egorov M, Aoun S, Padrines M, Redini F, Heymann D, Lebreton J, Mathe-Allaimat. A one-pot synthesis of 1-hydroxy-1,-diphosphonic acids starting from the corresponding carboxylic acids. Eur J Org Chem, 2011, 7148-7154.

141. Picarda G, Trichet V, Teletchea S, Heymann D, Redini F. TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res, 2011, 7: 23-38.

140. Baud'huin M, Ruiz-Velasco C, Jego G, Charrier C, Gasiunas N, Gallagher J, Maillasson M, Naggi A, Padrines M, Redini F, Duplomb L, Heymann D. Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol, 2011, 90:49-57.

139. Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother, 2011, 12: 285-292.

138. Peyrode C, Gouin F, Vidal A, Auzeloux P, Besse S, Dauplat MM, Askienazy S, Heymann D, Chezal JM, Redini F, Miot-Noirault E. 99mTc-NTP 15-5 Radiotracer for a molecular imaging of chondrosarcoma in nuclear medicine: proof of concept in rats. Sarcoma, 2011, 691608 (8 pages)

137. Saidi S, Bouri F, Lencel P, Duplomb L, Baud'huin M, Delplace S, Leterme D, Miellot F, Heymann D, Hardouin P, Palmer G, Magne D. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine, 2011, 53: 347-354.

136. David E, Guihard P, Brounais B, Riet A, Charrier C, Battaglia S, Gouin F, Ponsolle S, Le Bot R, Richards CD, Heymann D, Rédini F, Blanchard F. Direct anti-cancer effect of oncostatin M on chondrosarcoma. Int J Cancer, 2011, 128:1822-1835.

135. Ruiz-Velasco C, Baud'huin M, Sinquin C, Maillasson M, Heymann D, Coliec-Jouault S, Padrines M. Effects of a sulphated heparin-likeexopolysaccharide produced by Altermonas infernicus on bone biology. Glycobiology, 2011, 6: 781-795.

134. David E, Blanchard F, Heymann MF, De Pinieux G, Gouin F, Redini F, Heymann D. The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma, 2011, ID: 932451, 8 pages.

133. Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I, Bièche I, Smadja D, Galy-Fauroux I, Colliec-Jouault S, Fischer A, Boisson-Vidal C. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost, 2011, 9: 834-843.

132. Hérisson F, Heymann MF, Charrier C, Chétiveau M, Battaglia S, Pilet P, Krempf M, Lemarchand P, Heymann D, Gouëffic Y.Carotid And Femoral Atherosclerotic Plaques Show Different Patterns. Atherosclerosis, 2011, 216: 348-354.

131. Battaglia S, Dumoucel S, Chesneau J, Heymann MF, Picarda G, Gouin F, Corradini N, Heymann D, Redini F. Impact of onco-pediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res, 2011, 26: 2439-2451.

130. Oliver L, Hue E, Rossignol J, Bougras G, Hulin P, Naveilhan P, Heymann D, Lescaudron L, Vallette FM. Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation. PLoS ONE, 2011, 6:e19820.
129. Rousseau J, Escriou V, Lamoureux F, Brion R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Redini F, Trichet V. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res, 2011, 26: 2452-2462.

128. Heymann D and Redini F. Bone sarcomas: pathogenesis and new therapeutic approaches. BoneKey Reports 2011, 8: 402-414.

127. Picarda G, Odri G, Corradini N, Heymann D, Tirode F, Redini F. Targeting the bone microenvironment as a promising therapeutic approaches in Ewing's sarcoma. Trends Cancer Res 2011, 7: 23-38.

Articles published in 2010
126. Le Goff B, Soltner E, Maugars Y, Rédini F, Heymann D, Berthelot JM. Association of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loos in a rat model of collagen induced arthritis. Arthritis Res Ther, 2010, R185, 1-10.

125. Lézot F, Blin-Wakkach C, Thomas B, Castaneda B, Bolanos A, Hotton D, Sharpe P, Heymann D, Carles G, Gregoriadis A, Berdal A. Dlx homeobox gene expression in osteoclasts. J Cell Physiol, 2010, 223: 779-787.

124. Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, Gouin F, Duplomb L, Heymann D. Interleukin-34 is expressed by giant cell tumour of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol, 2010, 221: 77-86.

123. Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F. Preclinical evidence of using TRAIL in Ewing's sarcoma therapy: TRAIL inhibits tumor growth, prevents osteolysis and increases animal survival. Clin Cancer Res, 2010,16: 2363-2374.

122. Rousseau J, Escriou V, Parrot P, Picarda G, Charrier C, Scherman D, Heymann D, Rédini F, Trichet V. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther, 2010, 17 : 387-397.

121.
Le Goff B, Blanchard F, Berthelot JM, Heymann D
, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010, 77:201-215.

120. Perrot P, Rousseau J, Bouffaut A-L, Rédini F, Cassagnau E, Deschaseaux F, Heymann M-F, Heymann D, Duteille F, Trichet V, Gouin F. Safety concern between autologous fat graft, mesenchymal stem cells and osteosarcoma relapse. PLoS ONE, 2010, 5, e10999: 1-10.

119.
Ruiz Velasco C., Colliec-Jouault S., Redini F, Heymann D., Padrines M.  Proteoglycans on bone tumor development. Drug Discov Today, 2010, 15: 553-560.

118. Isidor B, Pichon O, Redon R, Day-Salvatore D, Hamel A, A. Siwicka K, Bitner-Glindzicz M, Heymann D, Kjellén L, Kraus C, G. Leroy J, Mortier GR, Rauch A, Verloes A,  David A, Le Caignec C. Mesomelia-synostoses syndrome results from deletion of SULF1 and SLCO5A1 genes at 8q13. Am J Human Genetic, 2010, 87: 95-100.

117. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des. 2010;16:2981-7.

116. Heymann D. Bisphosphonates and bone diseases: past, present and future (Editorial). Curr Pharm Des. 2010, 16:2948-9.

115. Heymann D
. Interleukin-34: an enigmatic cytokine. IBMS BoneKEY 2010, 7: 406-413.

114. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010, 70:7610-7619. Selected by the Faculty of 1000

113.
Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, Mönkkönen J, Rédini F, Heymann D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010, 70:10329-10339.

Articles published in 2009
112. Mori K, Ando K, Heymann D, Redini F. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumours through functional RANK expressed on bone associated cancer cells? Histol Histopathol, 2009, 24: 235-242.

111. Lamoureux F, Picarda G, Garrigue L, Baud'huin M, Trichet V, Vidal A, Miot-Noirault E, Pitard B, Heymann D, Redini F. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res, 2009, 69: 526-536.

110. Georges S, Ruiz Velasco C, Trichet V, Fortun Y, Heymann D, Padrines M. Proteases and bone remodelling. Cytokine Growth Factor Rev, 2009, 20:29-41.

109.
Brounais B, David E, Chipoy C, Trichet V, Ferre V, Charrier C, Duplomb L, Berreur M, Rédini F, Heymann D, Blanchard F. Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone, 2009, 44:830-839.

108. Miot-Noirault E, Gouin F, Vidal A, Rapp M, Maublant J, Askienazy S, Chezal JM, Heymann D, Redini F, Moins N. First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99Tc-NTP 15-5 radiotracer. J Nucl Med, 2009, 50:1541-1547.

107. Dechaseaux F, Sensébé L, Heymann D. The mechanism of bone repair and regeneration. Trends Mol Med, 2009, 563: 1-13.

106.
Baud'huin M, Duplomb L, Télétchéa S, Charrier C, Maillasson M, Fouassier M, Heymann D. Factor VIII/von Willebrand factor complex controls RANKL-induced osteoclastogenesis and cell survival. J Biol Chem, 2009, 264: 31704-31713

105.
Rossignol J, Boyer C, Thinard R, Remy S, Dugast AS, Dubayle D, Dey ND, Boeffard F, Delecrin J, Heymann D, Vandhove B, Anegon I, Naveilhan P, Dunbar GL, lescaudron L. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med, 2009,13: 2547-2558.

Articles published in 2008
104. Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, Duteille F, Heymann D, Rédini F. Relevance of a new rat syngenic model of osteoblastic metastases from prostate carcinoma for pre-clinical studies using zoledronic acid. Int J Cancer, 2008, 122: 751-760.

103. Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther, 2008, 8, 151-159.

102. Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers MJ, Heymann D. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med, 2008, 12, 928-941.

101. Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, Blanchard F, Heymann D. Interleukin-6 inhibits receptor activator of nuclear factor kB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of serine727 phosphorylation of signal transducer and activator of transcription factor 3. Endocrinology, 2008, 149: 3688-3697.

100.
Lamoureux F, Picarda G, Rousseau J, Gourden C, Battaglia S, Charrier C, Pitard B, Heymann D, Redini F. Therapeutic efficacy of soluble receptor activator of NF-kB delivered by non viral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther, 2008; 7: 3389-3398.